Dr González-González on DDR Pathway Inhibition in HER2-low TNBC Breast Cancer Models
April 12th 2023
Adrian González-González discusses findings from a preclinical study of trastuzumab deruxtecan in combination with DNA damage response (DDR) pathway inhibitors in xenograft models derived from patients with HER2-low triple-negative breast cancer.